On Friday, Versapay announced it had closed non-brokered private placement of 6.29 million common shares of the company at a price of $1.70 per common share for gross proceeds of approximately $10.7-million.
Kwan says this development changes not only the company’s cap structure, but its opportunities going forward.
“We understand that Fidelity accounted for most of the financing (~90%), with existing shareholder Stableview Asset Management accounting for the rest (~10%; maintaining their stake). Fidelity is now VPY’s largest shareholder, as it owns ~15% of the stock,” the analyst notes. “(The vote) of confidence from Fidelity and the large cash balance should help secure large enterprise customer wins and new channel partners. We believe the endorsement by Fidelity and the significantly strengthened balance sheet should go a long way in helping VPY win new large enterprise customers and channel partners (especially in the US) who may have previously been concerned about doing business with a small, emerging fintech (e.g., potential questions about their financial strength).”
In a research update to clients today, Kwan maintained his “Buy” rating on Versapay, but raised his one-year price target from $3.00 to $3.50, implying a return of 75 per cent at the time of publication.
Kwan thinks Versapay will generate EBITDA of negative $7.1-million on revenue of $2.7-million on fiscal 2017. He expects those numbers will improve to EBITDA of negative $3.1-million on a topline of $8.9-million the following year.
Haywood Securities analyst Neal Gilmer says lower Canadian cannabis market share is weighing on Tilray Brands (Tilray Brands Stock Quote,… [Read More]
National Bank Financial analyst Baltej Sidhu says Anaergia’s (Anaergia Stock Quote, Chart, News, Analysts, Financials TSX:ANRG) divestiture of two legacy… [Read More]
RBC assistant chief economist Cynthia Leach says the public sector is playing a larger role in Canada’s investment boom than… [Read More]
Research Capital analyst Andre Uddin says Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) reported another strong… [Read More]
Roth Capital Partners analyst Craig Irwin says VersaBank (VersaBank Stock Quote, Chart, News, Analysts, Financials NASDAQ:VBNK) is nearing a potential… [Read More]
Roth Capital Partners analyst Max Masucci says Rapid Micro Biosystems (Rapid Micro Biosystems Stock Quote, Chart, News, Analysts, Financials NASDAQ:RPID)… [Read More]